Weath­er­ing the storm: An­oth­er biotech braves Covid-19 in up­sized IPO

Zen­tal­is isn’t the on­ly biotech to de­fy ex­pec­ta­tions as fi­nan­cial mar­kets across the globe roil from the shock of the coro­n­avirus pan­dem­ic. Keros Ther­a­peu­tics has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER